ライフサイエンスコーパス: inhalational

1 Mice were challenged for one hour with inhalational 1.5% isoflurane, or intraperitoneal ketamin

2 AS pathway might be considered, for example, inhalational administration of ACEIs/ARBs (to deliver dr

3 phage administration was more effective than inhalational administration, suggesting that circulating

4 a progressive shift to using more expensive inhalational agents and total intravenous anesthesia in

5 rhaps even less effective, than titration of inhalational agents using end tidal anesthetic concentra

6 Among the inhalational agents, usage costs of sevoflurane and desf

7 Recording solutions were equilibrated with inhalational anaesthetic vapour delivered from a calibra

8 entobarbital, midazolam, propofol, ketamine, inhalational anaesthetics (isoflurane, desflurane), anti

9 ble individuals on exposure to commonly used inhalational anaesthetics and depolarising muscle relaxa

10 The effects of the inhalational anaesthetics halothane and isoflurane on th

11 olved in the mechanism of action of general (inhalational) anaesthetics.

12 s encountered in vivo, as well as in vivo in inhalational and cutaneous mouse models of B. anthracis

13 which can help prioritize efforts to reduce inhalational and dermal exposures.

14 s in acute adaptive immune responses between inhalational and dermal infection with F. tularensis LVS

15 me binding site mediates recognition of both inhalational and injectable anesthetics.

16 The comparison of inhalational and intravenous anaesthesia has been the su

17 would protect cortical neurons against both inhalational and intravenous anesthetic-induced neurotox

18 ns, we find that larval zebrafish respond to inhalational and IV anesthetics at concentrations simila

19 At an inhalational and oral dose of 10 mg (-)-Delta(9)-tetrahy

20 sia (TIVA) has better survival outcomes than inhalational anesthesia (INH) in several types of cancer

21 Bispectral index monitoring during inhalational anesthesia adds to the cost without providi

22 thesia offers a physiological advantage over inhalational anesthesia for thoracic surgery remain inco

23 cause temporary amnesia, yet the effects of inhalational anesthesia on human emotional memory proces

24 ed with lower incidence of laryngospasm than inhalational anesthesia.

25 esthetized with a virtually nondefluorinated inhalational anesthetic (desflurane) or with a nonfluori

26 advantages for any of the commonly available inhalational anesthetic agents and each can be used for

27 Inhalational anesthetic agents have also been shown to r

28 Xenon and dichloromethane are inhalational anesthetic agents whose binding to myoglobi

29 ative, analgesics, benzodiazepines, opioids, inhalational anesthetic agents, nitrous oxide, ketamine,

30 ous oxide (N2O, laughing gas), a widely used inhalational anesthetic and drug of abuse.

31 To identify inhalational anesthetic binding domains in a ligand-gate

32 To determine inhalational anesthetic binding domains on a ligand-gate

33 during surgery (derived from mean end-tidal inhalational anesthetic concentrations).

34 Inhalational anesthetic dose increase and reduced risk o

35 High inhalational anesthetic dose of 1.20 (1.13-1.30) (median

36 We sought to determine the effect of inhalational anesthetic dose on risk of severe postopera

37 Additionally, high inhalational anesthetic dose was associated with lower 3

38 Intraoperative use of higher inhalational anesthetic doses is strongly associated wit

39 can be utilized to probe the binding of the inhalational anesthetic halothane to an anesthetic-bindi

40 amuscular sedative was given, followed by an inhalational anesthetic induction and mechanical ventila

41 iments were performed with the commonly used inhalational anesthetic sevoflurane.

42 ectroscopic probe to study the binding of an inhalational anesthetic to a model membrane protein.

43 Clinical concentrations of the inhalational anesthetic, halothane (1 rat MAC, 1.2 vol.%

44 Isoflurane, the most widely used inhalational anesthetic, releases inorganic fluoride dur

45 We now report that inhalational anesthetics affect gene expression of nitri

46 ersing the effects of some anesthetic drugs (inhalational anesthetics and muscle relaxants) are descr

47 This is a novel interaction between inhalational anesthetics and the NO signaling pathway an

48 Inhalational anesthetics are bronchodilators with immuno

49 They also received inhalational anesthetics because of refractory bronchoco

50 Postconditioning with inhalational anesthetics can reduce ischemia-reperfusion

51 At surgical depths of anesthesia, inhalational anesthetics cause a loss of motor response

52 These data indicate that inhalational anesthetics cause activation of RTN neurons

53 Currently, it is thought that inhalational anesthetics cause anesthesia by binding to

54 e that clinically relevant concentrations of inhalational anesthetics dose-dependently and specifical

55 Median effective dose equivalent of inhalational anesthetics during surgery (derived from me

56 Inhalational anesthetics have been shown to inhibit the

57 Increasing use of inhalational anesthetics in the ICU underscores the need

58 sting differences in the binding domains for inhalational anesthetics in the nAChR.

59 sthesia is indicated for procedures in which inhalational anesthetics may not be safely or effectivel

60 w that clinically relevant concentrations of inhalational anesthetics modulate neuronal Ih and the co

61 A better understanding of the effect of inhalational anesthetics on fetal cardiac function and s

62 The potential adverse impact of inhalational anesthetics on the developing brain was hig

63 ulate based on these data that sedation with inhalational anesthetics outside of the operating room m

64 The molecular pharmacology of inhalational anesthetics remains poorly understood.

65 in experimental traumatic brain injury with inhalational anesthetics, these results indicate that th

66 the native RTN current (i.e., suppression by inhalational anesthetics, weak rectification, inhibition

67 ures incompatible with effective delivery of inhalational anesthetics.

68 lar concentration is central to the study of inhalational anesthetics.

69 ose receptors is less certain in the case of inhalational anesthetics.

70 the PDZ domain as a new molecular target for inhalational anesthetics.

71 Administration of inhalational anesthetics.

72 Prevention of inhalational anthrax after Bacillus anthracis spore expo

73 ber 19 and October 26, there were 5 cases of inhalational anthrax among postal workers who were emplo

74 py appears to have slowed the progression of inhalational anthrax and has resulted to date in surviva

75 otic prophylaxis required to protect against inhalational anthrax and may impact public health manage

76 osed to prophylaxis, could effectively treat inhalational anthrax and prevent disease caused by the g

77 d cough do not reliably discriminate between inhalational anthrax and viral respiratory tract infecti

78 The cases of 2 postal workers who died of inhalational anthrax are reported here.

79 conduct credible human risk assessments for inhalational anthrax associated with exposure to a low n

80 es are decisive events in the progression of inhalational anthrax because they initiate germination a

81 Also, rabbits that were protected from inhalational anthrax by administration of ETI-204 develo

82 atocrit were more frequently recorded in the inhalational anthrax cases than in either the community-

83 Inhalational anthrax caused by Bacillus anthracis is ass

84 of patients who died of bioterrorism-related inhalational anthrax confirmed the route of infection.

85 This study demonstrated that the course of inhalational anthrax disease and the resulting pathology

86 ant importance to reassess the mechanisms of inhalational anthrax dissemination, since it is this for

87 Mortality from inhalational anthrax during the 2001 U.S. attack was sub

88 g the recent bioterrorism-related outbreaks, inhalational anthrax had a 45% mortality in spite of app

89 Inhalational anthrax has characteristic clinical feature

90 had been mailed to a US senator, 5 cases of inhalational anthrax have occurred among postal workers

91 adenopathy led to a presumptive diagnosis of inhalational anthrax in both cases.

92 is capsule and toxins in the pathogenesis of inhalational anthrax in rabbits by comparing infection w

93 of rPA provides complete protection against inhalational anthrax in rabbits.

94 identification of patients with presumptive inhalational anthrax in the setting of a large-scale ant

95 l history, pathophysiology, and pathology of inhalational anthrax in this animal model following nose

96 ed attenuated virulence in a murine model of inhalational anthrax infection.

97 udies aiming to understand events initiating inhalational anthrax infections.

98 The rabbit model of inhalational anthrax is an important tool in the assessm

99 Inhalational anthrax is caused by inhalation of Bacillus

100 Inhalational anthrax is caused by the sporulating bacter

101 's high index of suspicion, the diagnosis of inhalational anthrax is difficult during nonspecific pro

102 Inhalational anthrax is initiated by the entry of Bacill

103 ed public health responses to an outbreak of inhalational anthrax is the optimum duration of antibiot

104 advances in supportive care, fulminant-phase inhalational anthrax is usually fatal.

105 rax attack, mass screening to identify early inhalational anthrax may improve both the management of

106 istorical data sets from West Nile virus and inhalational anthrax outbreaks.

107 th authorities investigated 11 patients with inhalational anthrax related to a bioterrorism attack in

108 scribe the 11th case of bioterrorism-related inhalational anthrax reported in the United States.

109 has been proposed that the dissemination of inhalational anthrax required spores to be transported f

110 Postexposure prophylaxis of inhalational anthrax requires prolonged antibiotic thera

111 CT) findings in two patients with documented inhalational anthrax resulting from bioterrorism exposur

112 is developed to analyze the transmission of inhalational anthrax through the postal system by cross-

113 CR and MCR model appeared to describe rabbit inhalational anthrax well.

114 competing risks (CR) computational model of inhalational anthrax where data was collected from NZW r

115 Aerosol challenge of guinea pigs resulted in inhalational anthrax with death occurring between 46 and

116 g was 100% sensitive (95% CI 84.6-100.0) for inhalational anthrax, 71.8% specific (64.8-78.1) compare

117 Inhalational anthrax, a disease caused by inhaling Bacil

118 osure to Bacillus anthracis spores initiates inhalational anthrax, a life-threatening infection.

119 of the central stages in the progression of inhalational anthrax, and it is commonly believed that t

120 are likely the first immune cells exposed to inhalational anthrax, and the interferon (IFN) response

121 R/MCR model with other computation models of inhalational anthrax, and using the resulting informatio

122 During inhalational anthrax, Bacillus anthracis survives and re

123 The etiologic agent of inhalational anthrax, Bacillus anthracis, produces virul

124 60 days of antibiotic prophylaxis to prevent inhalational anthrax, but adherence to this regimen was

125 York City hospital employee developed fatal inhalational anthrax, but with an unknown source of anth

126 Bacillus anthracis, the causative agent of inhalational anthrax, enters a host through the pulmonar

127 In contrast to events in experimental inhalational anthrax, spore germination in these cutaneo

128 significantly attenuated in a mouse model of inhalational anthrax, suggesting that the microarray dat

129 In the treatment of inhalational anthrax, the prolonged course of antibiotic

130 To identify clinical characteristics of inhalational anthrax, we compared 47 historical cases (i

131 Although several factors contribute to inhalational anthrax, we hypothesized that unimpeded inf

132 scription of the early infection dynamics of inhalational anthrax, while its stochastic nature allows

133 teritis; however, some recent isolates cause inhalational anthrax-like diseases and death.

134 icrobial activity, we used a murine model of inhalational anthrax.

135 ival in rabbits and monkeys with symptomatic inhalational anthrax.

136 use aerosol challenge model for the study of inhalational anthrax.

137 one and completely protected animals against inhalational anthrax.

138 urrently no approved effective treatment for inhalational anthrax.

139 tive therapy for prevention and treatment of inhalational anthrax.

140 ts toward identifying clinical predictors of inhalational anthrax.

141 s an endospore-forming bacterium that causes inhalational anthrax.

142 The cause of death was inhalational anthrax.

143 tes, but tragically some individuals died of inhalational anthrax.

144 as been described as the classic pattern for inhalational anthrax.

145 ) in order to explain dose-response data for inhalational anthrax.

146 Bacillus anthracis can cause inhalational anthrax.

147 vivo NK cell depletion in a murine model of inhalational anthrax.

148 ignificantly attenuated in a murine model of inhalational anthrax.

149 des unique insight into host defense against inhalational anthrax; these data also support the notion

150 Inhalational antibiotics reduce the bacterial burden ass

151 Both viral infection and inhalational antigen challenge cause M(2)R dysfunction,

152 Airway eosinophils, recovered after inhalational antigen challenge in sensitized mice, expre

153 ent mice, airway eosinophils recovered after inhalational antigen challenge stimulated antigen-specif

154 We examined in vivo whether pre-existing inhalational antigen tolerance could be overcome by acti

155 Inhalational antigen tolerance typically protects agains

156 ice with lethal disseminated candidiasis and inhalational aspergillosis.

157 nge, the lungs of C57BL/6 mice (resistant to inhalational B. anthracis infection) had significantly h

158 Murine inhalational B. anthracis infections have two portals of

159 for the high mortality rates associated with inhalational Bacillus anthracis infection.

160 s applied to serum from rhesus macaques with inhalational botulism following exposure to BoNT/B, show

161 erize the rhesus macaque (RM) as a model for inhalational brucellosis in support of the U.S. Food and

162 ort the use of the RM as an animal model for inhalational brucellosis to evaluate the efficacy of nov

163 clinical presentation and pathophysiology of inhalational brucellosis, Balb/c mice were challenged wi

164 l for the evaluation of therapeutics against inhalational brucellosis.

165 induce a humoral immune response to a single inhalational challenge to HDM.

166 Capsaicin inhalational challenge was performed, and cough response

167 complete or nearly complete protection from inhalational challenge with 100% lethal doses of B. mall

168 and Hcp1, 100% of the mice survived a lethal inhalational challenge with B. pseudomallei Remarkably,

169 resulted in enhanced levels of IL-17A after inhalational challenge with HDM.

170 Inhalational challenges to histamine and methacholine (M

171 can be used to quantitate levels of skin and inhalational contact with simulant pathogen particles.

172 second only to carbon monoxide as a cause of inhalational deaths.

173 of inhaled antifungal drugs and combination inhalational devices, limitations of existing nonclinica

174 nited States in 2001 resulted in 11 cases of inhalational disease, with an attendant mortality rate o

175 Substance use, and especially inhalational drug use, increases the likelihood of both

176 Patients with inhalational dyspnea attributed to ILO were included.

177 n contamination (via swabbing) and potential inhalational exposure (via breathing zone air sampler).

178 terium and Selenomonas, indicating that this inhalational exposure can alter the composition of the s

179 y of the human health risk assessment due to inhalational exposure to 1,3-butadiene (BD) and styrene

180 o were referred for evaluation, a history of inhalational exposure to a 2003 sulfur-mine fire in Iraq

181 indicates that adverse health effects due to inhalational exposure to BD and ST for workers in the ma

182 Following inhalational exposure to Francisella tularensis SCHU S4,

183 developed a model of airway inflammation and inhalational exposure to investigate regulatory pathways

184 a in female Fischer 344 rats after nose-only inhalational exposure to lethal doses of aerosolized Fra

185 Continuous inhalational exposure to OVA (6 or 11 weeks) resulted in

186 Discontinuous inhalational exposure to OVA (6 weeks) produced airway i

187 In humans, inhalational exposure to particulate air pollutants decr

188 , while the air sampler quantified potential inhalational exposure to PSLs during doffing.

189 o products, including waterpipes, are due to inhalational exposure to toxicants either present in tob

190 hiolitis, which was possibly associated with inhalational exposure, in 38 soldiers.

191 e cause such as collagen vascular disease or inhalational exposure.

192 ysis showed significant associations between inhalational exposures (cigarette smoking, waterpipe smo

193 However, the impact of inhalational exposures (eg, vapor, dust, gas, fumes), wh

194 These results suggest that occupational inhalational exposures are independently associated with

195 soldiers from Fort Campbell, Kentucky, with inhalational exposures during service in Iraq and Afghan

196 Toxicity classically results from inhalational exposures in individuals who work in indust

197 These findings suggest that certain military inhalational exposures may contribute to the development

198 Our findings emphasize the impact of inhalational exposures on gastrointestinal disease risk,

199 atients with lung disease from other ongoing inhalational exposures, including avian antigens in chro

200 ts should be alert to avoid excessively high inhalational flow.

201 The inhalational form of anthrax is the most severe and is a

202 of IL-17A and IFN-gamma in the lungs during inhalational Francisella infection and that these cytoki

203 We hypothesized that nitrous oxide, an inhalational general anesthetic and N-methyl-D-aspartate

204 We have previously shown that recognition of inhalational general anesthetics by the model protein ap

205 Inhalational general anesthetics have recently been show

206 + channels strongly suggest that halogenated inhalational general anesthetics interact with gates and

207 coccus neoformans H99 infection by comparing inhalational H99 infections in wild-type BALB/c and IL-4

208 Rationale: Workplace inhalational hazards remain common worldwide, even thoug

209 phics of research studies with intranasal or inhalational ICS.

210 olam formulated in flavoured syrups, and the inhalational induction of anaesthesia may be accomplishe

211 on has become the most widely cited model of inhalational infection as well as the focus of the major

212 that bacterial dissemination patterns during inhalational infection may be more similar to the cutane

213 compared in both the murine intravenous and inhalational infection models, there were significant di

214 es an attractive strategy to protect against inhalational infection with virulent B. melitensis.

215 Using a clinically relevant mouse model of inhalational infection with virulent C. neoformans H99,

216 oning, fire-related toxic gas exposures, and inhalational injuries.

217 In a sulfur dioxide (SO2) inhalational injury model, bromodeoxyuridine (BrdU) inco

218 While inhalational injury to the airway epithelium is suspecte

219 but it may not have a role in patients with inhalational injury.

220 ly an adult disease occurring after years of inhalational insults to the lungs, pinpointing abnormali

221 f-renew and critical to the health impact of inhalational insults.

222 ly used volatile anesthetic, and is used for inhalational long-term sedation in critically ill patien

223 The term inhalational lung disease comprises a group of entities

224 Inhalational lung diseases are classified as occupationa

225 results define early events occurring in an inhalational macaque monkeypox infection model, supporti

226 rranted to confirm the effectiveness of this inhalational method.

227 t than the control strains in both the mouse inhalational model and the rabbit meningitis model.

228 conducted in the African green monkey (AGM) inhalational model of pneumonic plague to test the effic

229 e and the reconstituted strain in the murine inhalational model, and it also had significantly impair

230 In this inhalational model, toxins have disseminated rapidly in

231 measured by cumulative survival in the mouse inhalational model.

232 measured by cumulative survival in the mouse inhalational model.

233 Here, the early pathogenic events of inhalational monkeypox infection in NHPs were characteri

234 Inhalational MtbDeltasigH, a stress-response-attenuated

235 ing peak nasal inspiratory flow and absolute inhalational nasal partitioning ratio) improved more in

236 acute respiratory distress syndrome (ARDS), inhalational NO has proved to be useful.

237 whatever the route of infection (cutaneous, inhalational, or digestive).

238 Inhalational plague in the cynomolgus macaque inoculated

239 All control animals in the inhalational plague studies succumbed to plague and were

240 ls, are >=90% effective for the treatment of inhalational plague when administered within 2-6 hours o

241 Inhalational pneumonic tularemia, caused by Francisella

242 (NASBA) method was investigated by use of an inhalational rat model of IPA.

243 a civilian or military population through an inhalational route of exposure and aerosol is considered

244 administration of drugs to the lung via the inhalational route provides for high concentrations at t

245 GA) during surgery is commonly maintained by inhalational sevoflurane.

246 Asthma lightened by treatment of inhalational steroids.

247 Comparing disease manifestations, inhalational survivors reported significantly lower over

248 Hence, adding inhalational to oral therapy can potentially accelerate

249 solution of AAD and the development of local inhalational tolerance (LIT).

250 ent resolution with the development of local inhalational tolerance (LIT).

251 appaB activation orchestrate the breaking of inhalational tolerance and allergic antigen sensitizatio

252 Inhalational tolerance induced by continuous OVA exposur

253 aled OVA on Day 30 in an attempt to overcome inhalational tolerance.

254 therefore, reveals novel mechanisms for the inhalational toxicity of vaping.

255 bitor, showed favorable pharmacokinetics for inhalational treatment and intranasal insufflation deliv

256 Migraine-like pain was also induced by inhalational umbellulone, a TRPA1 agonist, in animals pr

257 subthreshold (i.e. second-hit) stimulus from inhalational umbellulone, a TRPA1 agonist.

258 es developed periorbital allodynia following inhalational umbellulone.

259 ment strategies augment the response to this inhalational vasodilator.

260 MH is a severe reaction triggered by inhalational volatile anesthetics and succinylcholine in

261 s: Together, these findings demonstrate that inhalational wood smoke exposure can modify several low-

262 at a delayed HMBPP/IL-2 administration after inhalational Yersinia pestis infection induced marked ex